























ORIGINAL ARTICLE OPEN ACCESS

Family History and Solar Insolation in Bipolar I Disorder

M. Bauer¹ | T. Glenn² | E. D. Achtyes³ | M. Alda⁴ | E. Agaoglu⁵ | K. Altınbaş⁶ | O. A. Andreassen⁷ | E. Angelopoulos⁸ | R. Arda⁹ | M. Aydin¹⁰ | Y. Ayhan⁵ | C. Baethge¹¹ | R. Bauer¹ | B. T. Baune^{12,13,14} | C. Balaban¹⁵ | C. Becerra-Palars¹⁶ | A. P. Behere¹⁷ | H. Belete¹⁸ | T. Belete¹⁸  | G. Okawa Belizario¹⁹ | F. Bellivier²⁰ | R. H. Belmaker²¹ | F. Benedetti^{22,23} | M. Berk^{24,25}  | Y. Bersudsky²⁶ | Ş. Bicakci^{5,27} | H. Birabwa-Oketcho²⁸ | T. D. Bjella⁷ | C. Brady²⁹ | J. Cabrera³⁰ | M. Cappucciati³¹ | A. M. Paredes Castro²⁴ | W. Chen³² | E. Y. W. Cheung³³ | S. Chiesa³¹ | M. Chanopoulou³⁴ | M. Crowe³⁵  | A. Cuomo³⁶ | S. Dallspezia²³ | P. Desai³⁷ | S. Dodd^{24,38} | B. Etain²⁰ | A. Fagiolini³⁶  | F. T. Fendler³⁹ | E. Ferenczajn-Rochowiak⁴⁰ | J. G. Fiedorowicz⁴¹ | K. N. Fountoulakis³⁴ | M. A. Frye⁴²  | P. A. Geoffroy^{43,44,45,46} | M. J. Gitlin⁴⁷ | A. Gonzalez-Pinto⁴⁸ | J. F. Gottlieb⁴⁹ | P. Grof⁵⁰  | B. C. M. Haarman⁵¹ | H. Harima⁵² | M. Hasse-Sousa^{53,54} | C. Henry⁴⁶ | L. Hoffding⁵⁵ | J. Houenou^{56,57} | M. Imbesi³¹ | E. T. Isometsä^{58,59} | M. Ivkovic⁶⁰ | S. Janno⁶¹ | S. Johnsen⁶² | F. Kapczinski⁵³ | G. N. Karakatsoulis³⁴ | M. Kardell⁶³ | L. V. Kessing⁶⁴  | S. J. Kim⁶⁵  | B. König⁶⁶ | T. L. Kot⁶⁷ | M. Koval⁶⁸ | M. Kunz⁵³ | B. Lafer¹⁹ | M. Landén^{63,69} | E. R. Larsen⁷⁰ | R. W. Licht^{71,72} | V. M. Ludwig¹ | C. Lopez-Jaramillo⁷³ | A. MacKenzie⁷⁴ | H. Østergaard Madsen⁷⁵ | S. Alberte Kongstad A. Madsen⁶² | J. Mahadevan⁷⁶ | A. Mahardika⁷⁷ | K. Mahfoudh⁷⁸ | M. Manchia^{79,80,81}  | W. Marsh⁸² | M. Martinez-Cengotitabengoa^{83,84,85} | J. Martini¹ | K. Martiny⁷⁵ | Y. Mashima⁸⁶ | D. M. McLoughlin⁸⁷  | A. N. R. Meesters⁵¹ | Y. Meesters⁵¹ | I. Melle⁷ | F. Meza-Urzuá⁸⁸ | E. Michaelis¹ | P. Mikolas¹ | Y. Ming Mok⁸⁹ | S. Monteith⁹⁰ | M. Moorthy⁷⁶ | G. Morken^{91,92} | E. Mosca⁹ | A. A. Mozzhegorov⁹³ | R. Munoz⁹⁴ | S. V. Myhri⁹⁵ | R. K. Nadella⁹⁶  | T. Nakanotani⁹⁷ | R. Ernst Nielsen^{71,72} | C. O'Donovan⁴ | A. Omrani⁹⁸ | Y. Osher²⁶ | U. Ouali⁷⁸  | M. Pantovic-Stefanovic⁶⁰ | P. Pariwatcharakul⁹⁹  | J. Petite⁴ | A. Pfennig¹ | M. Pilhatsch¹ | Y. Pica Ruiz¹⁰⁰ | M. Pinna^{82,101} | M. Pompili¹⁰²  | R. Porter³⁵  | D. Quiroz¹⁰³ | F. Diego Rabelo-da-Ponte¹⁰⁴ | R. Ramesar¹⁰⁵ | N. Rasgon¹⁰⁶ | W. Ratta-apha⁹⁹ | M. Redahan²⁹ | M. S. Reddy¹⁰⁷ | A. Reif^{15,96} | E. Z. Reininghaus³⁹ | J. Gringer Richards¹⁰⁸ | P. Ritter¹  | J. K. Rybakowski⁴⁰  | L. Sathyaputri¹⁰⁸ | A. M. Scippa¹⁰⁹ | C. Simhandl¹¹⁰ | D. Smith¹¹¹ | J. Smith¹¹² | P. W. Stackhouse Jr¹¹³ | D. J. Stein¹¹⁴  | K. Stilwell³⁷ | S. Strejilevich¹¹²  | K.-P. Su^{115,116} | M. Subramaniam¹¹⁷  | A. Hatim Sulaiman¹¹⁸ | K. Suominen¹¹⁹ | A. J. Tanra¹²⁰ | Y. Tatebayashi⁹⁷ | W. Lin Teh¹¹⁷ | L. Tondo^{121,122} | C. Torrent^{123,124} | D. Tuinstra³⁷ | T. Uchida^{84,125} | A. E. Vaaler^{91,92}  | E. Vieta¹²⁴  | B. Viswanath⁷⁵ | C. Volf⁷⁴ | K.-J. Yang¹¹⁴ | M. Yoldi-Negrete¹²⁶  | O. Kaan Yalcinkaya⁵ | A. H. Young¹²⁷ | Y. Zgueb⁷⁷ | P. C. Whybrow⁴⁷

Correspondence: M. Bauer (michael.bauer@ukdd.de)

Received: 8 August 2025 | **Revised:** 17 November 2025 | **Accepted:** 19 January 2026

ABSTRACT

Background: Sunlight has profound impacts on physical and mental health, beyond vision, including effects on circadian rhythms, alertness, mood, and sleep. A family history of any mood disorders is strongly associated with psychiatric disorders including bipolar disorder. The purpose of this study was to evaluate the association between a family history of any mood disorder in patients with bipolar I disorder and solar insolation at varied international onset locations.

Methods: Data for this analysis were available from 5842 patients with a diagnosis of bipolar I disorder obtained at 83 collection sites in both hemispheres. This included 4752 patients from 71 collection sites in the northern hemisphere and 1090 patients from 12 collection sites in the southern hemisphere. Patient data variables were obtained from records or interviews. Solar insolation data were obtained from The National Aeronautics and Space Administration (NASA) Power database for each onset location, and the ratio of the mean monthly minimum/mean monthly maximum solar insolation was calculated. Typically, the ratio is largest near the equator (little yearly change in solar insolation) and smallest near the poles (large yearly change in solar insolation).

This research is dedicated to Professor Peter C. Whybrow, MD, DPM, MB, FRCP who died on 25th August 2025.

For affiliations refer to page 275.

[Correction added on 13 March 2026, after first online publication: The affiliation 'Basque Sustainable Pharmacy and Biotherapy Research Group, BioAraba Health Research Institute and Neurohealth Research Group' has been added for M. Martinez-Cengotitabengoa.]

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Acta Psychiatrica Scandinavica* published by John Wiley & Sons Ltd.

Results: A significant relationship was found between a family history of any mood disorder, the ratio of the mean monthly minimum/mean monthly maximum solar insolation, and gender. The odds of a family history of mood disorder increased as patient location nears the poles and decreased near the equator. Female gender also increased the odds of having a family history of a mood disorder.

Conclusions: This study highlighted the association between family history, solar insolation, and gender in international patients with bipolar I disorder. Given the profound effects of sunlight on human health, the family of patients with bipolar disorder who live in the same location with the same solar insolation, and especially females, may be at increased risk for a mood disorder.

1 | Introduction

Sunlight has a profound, diverse influence on human physiology and health that extends beyond vision, including effects on circadian rhythms, mood, alertness, and sleep [1–3]. The pattern of solar insolation across the earth's surface varies with the annual changes in the relationship between the earth and sun, and differs by latitude [4]. Using sunlight measured as solar insolation (incoming solar radiation on the surface of the earth), we previously investigated the effects of changes in solar insolation using a large, international database of patients with bipolar I disorder (BD I) from multiple continents and found that the maximum monthly increase in solar insolation was inversely related to the age of onset of BD I [5, 6].

Sunlight is the strongest signal used to synchronize human circadian clocks to the 24h rotation of the Earth [7, 8]. Nearly all human physiological processes include circadian timing cycles, with a master pacemaker in the suprachiasmatic nucleus and organized peripheral cells containing clock components to produce circadian rhythms [9, 10]. In addition to rods and cones, melanopsin is a special photopigment in the eye that responds to light in the environment [11]. Disruptions in circadian rhythms are associated with a variety of acute and chronic health problems, both physical and mental, including sleep and mood disturbances in bipolar disorder [1, 12–14]. Additionally, sunlight exposure is the primary source of Vitamin D for both adults and children [15]. The purpose of this analysis was to examine and clarify the relationship between a family history of any mood disorder for patients with BD I and solar insolation at varied onset locations.

2 | Aim of the Study

Given the importance of sunlight on human physical and mental health, the aim of this study was to investigate the relationship between solar insolation and a family history of any mood disorder in patients with BD I, using a large, international database with locations extending from the poles to the equator.

3 | Methods

3.1 | Patient Data Collection

All patients in the study received a diagnosis of BD I from a psychiatrist according to DSM-IV, DSM-5, or ICD criteria. Data were obtained by direct questioning, record review, or both, from individual practitioners, medical centers, and specialty clinics. Approval from local institutional review boards was obtained

according to local requirements. The data collected for each patient included diagnosis, gender, age of onset, date of birth, polarity of first episode, family history of mood disorders (other than the patient), history of psychosis, episode course, history of alcohol or substance abuse, history of suicide attempts, birth location, onset location, and current location. Data were collected from 8657 patients with BD I disorder. Patients were excluded if they were missing family history, gender, or if they had different birth and onset locations, leaving 5842 patients with BD I for the analysis. Of the 5842 patients, 4752 were from the northern hemisphere and 1090 from the southern hemisphere.

Data were obtained from 83 collection sites with 71 locations in the northern hemisphere and 12 in the southern hemisphere. In the northern hemisphere, data collection sites included: Austria: Graz, Wiener Neustadt; Canada: Calgary, Halifax, Ottawa; China: Hong Kong; Colombia: Medellín; Denmark: Aalborg, Aarhus, Copenhagen, Odense; Ethiopia: Barhir Dar; Estonia: Tartu; Finland: Helsinki; France: Paris (2 sites); Germany: Dresden, Frankfurt, Würzburg; Greece: Athens, Thessaloniki (2 sites); India: Bengaluru, Hyderabad, Wardha; Ireland: Dublin; Israel: Beer Sheva; Italy: Cagliari, Sardinia (2 sites), Milan, Piacenza, Rome, Siena; Japan: Chiba, Tokyo (3 sites); Malaysia: Kuala Lumpur; Mexico: Mexico City; Netherlands: Groningen; Norway: Oslo, Trondheim; Poland: Poznan; Russia: Khanti-Mansiysk; Serbia: Belgrade; Singapore; South Korea: Jincheon; Spain: Barcelona, Vitoria; Sweden: Gothenburg, Stockholm; Taiwan: Taichung; Thailand: Bangkok; Turkey: Ankara, Konya; Tunisia: Tunis; Uganda: Kampala; UK: Glasgow; and USA: Grand Rapids, MI, Iowa City, IA, Kansas City, KS, Los Angeles, CA, Palo Alto, CA, Rochester, MN, and San Diego, CA. In the southern hemisphere, data collection sites included: Australia: Adelaide; Argentina: Buenos Aires; Brazil: Porto Alegre, Salvador, São Paulo; Chile: Santiago (2 sites); Indonesia: Mataram; New Zealand: Christchurch; and South Africa: Cape Town.

3.2 | Statistics

The generalized estimating equations (GEE) statistical technique was used to account for both the correlated data and unbalanced number of patients at collection sites. The GEE technique estimates the dependent variable as a function of the entire population, rather than within a cluster, producing a population averaged or marginal estimate of model coefficients [16]. All GEE models were estimated using a binomial distribution, an exchangeable working correlation matrix, and a logit link function where family history of mood disorders was the dependent binary variable. Confidence intervals at the 0.01 significance level were used to reduce the chance of type 1 errors.

Summary

- Significant outcomes
 - There is a significant association between family history of a mood disorder, solar insolation, and gender in international patients with bipolar I disorder.
 - The odds of a family history of a mood disorder increase as patient location nears the poles and decrease near the equator.
 - Family members who live in the same location and experience the same solar insolation, especially females, may be at increased risk for a mood disorder.
- Limitations
 - Family history was obtained from patient data. Family members were not interviewed.
 - Unique patient light exposure data was not obtained.
 - Individual patient sensitivity to light was not analyzed.

Demographic variables were reported using descriptive statistics. SPSS version 30.0 was used for all analyses.

Because the patient birth and onset locations were the same, the insolation values at the patient onset location were used as a proxy for other family members to evaluate the family history. While this assumption may be imperfect, it provides an approximate estimate of insolation for family members.

3.3 | Solar Insolation

The solar insolation data were obtained from The National Aeronautics and Space Administration (NASA) Power database [4]. Solar insolation refers to the amount of electromagnetic energy from the sun received on earth for a given surface area at a given time, expressed as kilowatt hour/square meter/day (kWh/m²/day). The yearly pattern of solar insolation varies by latitude, with few monthly changes at the equator and large changes near the poles. Various other factors also influence solar insolation values, including time of day, altitude, season, local weather, and atmospheric conditions such as air pollution [4, 17]. Rather than a winter summer pattern, tropical locations (less than 23.5° latitude) may have a wet season where clouds decrease insolation and a dry season with clear skies.

To accommodate tropical locations, the ratio of mean monthly minimum/mean monthly maximum insolation was used to summarize insolation. Locations where the ratio of mean monthly minimum/mean monthly maximum insolation is near zero are typically near the poles and locations where the ratio of mean monthly minimum/mean monthly maximum insolation is near 1 are typically near the equator. Locations at the same latitude may have different solar insolation due to local conditions such as cloud cover, aerosols, altitude, and proximity to water.

4 | Results

The demographics of the 5842 patients are shown in Table 1. The mean age at the time of data collection was 47.0 (14.6), and the mean age of onset was 25.2 (10.4). The GEE logistic regression model estimated the family history of mood disorders for a patient using the ratio of mean monthly minimum/mean monthly maximum insolation and gender. See Table 2,3. The odds of a family history of mood disorders decreased as family location approached the equator and increased toward the poles. For example, if a patient and their family living in Minneapolis, MN, USA are compared to a patient and family living in Los Angeles, CA, USA, the ratio of the mean monthly minimum/mean monthly maximum insolation is 0.1567 higher in Los Angeles. This difference translates into a 12.4% $((0.211-1) * 0.1567)$ decrease in the odds ratio for a family history of mood disorders for the family living in Los Angeles. See Table 3. The independent variables for the model were limited to insolation at the patient's onset location and the patient's gender to minimize the possibility of overfitting a model that is estimated with imprecise data. See Table 3 for example collection locations with their ratio of mean monthly minimum/mean monthly maximum insolation values. If gender is female, the odds ratio of a family history of mood disorders increases by 21.7% compared to a male patient.

5 | Discussion

Sunlight has widespread important impacts on the physiological and mental health of humans. Although most public education is focused upon the risks associated with excessive

TABLE 1 | Demographics of bipolar I patients (N = 5842).

Parameter	Value	N	%
Gender	Female	3364	57.6
	Male	2478	42.4
Family history of mood disorder	No	2847	48.7
	Yes	2995	51.3
Cohort group	DOB ^a < 1940	196	3.4
	DOB ≥ 1940 and DOB < 1960	1339	22.9
	DOB ≥ 1960 and DOB < 1980	2709	46.4
	DOB ≥ 1980	1598	27.4
Parameter		Mean	SD
Age at time of data collection		47.0	14.6
Age of onset		25.2	10.4

^aDOB, date of birth.

TABLE 2 | Estimated parameters explaining family history of mood disorders for patients with bipolar I disorder using ratio of mean monthly minimum/mean monthly maximum insolation and gender ($N=5842$).^a

Parameter	df	Sig	exp (B) ^b	99% Wald confidence interval for exp (B)	
				Lower	Upper
Intercept	1	<0.001	1.617	1.226	2.133
Ratio mean monthly minimum/mean monthly maximum insolation	1	<0.001	0.211	0.111	0.400
Gender = 0 (female)	1	<0.001	1.217	1.057	1.400

^aDependent variable: Family history of mood disorders (yes/no). Model: intercept, ratio of mean monthly minimum/mean monthly maximum insolation and gender (male/female).

^bExp (B) is the exponentiated value of the estimated coefficient B.

sunlight exposure, it is important to recognize the fundamental role of sunlight in human life and health. In addition to providing sufficient light for comfortable vision, sunlight exposure is related to vitamin D production, maintaining circadian rhythms, sleep-wake cycles, well-being and mood, cognition, and regulation of neuroendocrine, cardiovascular, and metabolic functions [18–23]. The effects of sunlight occur through three main routes: vision, skin absorption, and the non-visual retinal responses to light that drive the circadian clock system and other neuronal pathways. In this analysis, we found that there was a significant relationship between a family history of any mood disorder, the ratio of the mean monthly minimum/mean monthly maximum solar insolation, and gender for patients with bipolar I disorder. This suggests a possible interaction between genetic vulnerability and environmental light exposure. In families with genetic susceptibility for bipolar disorder, the local light environment may lower the threshold for illness expression.

5.1 | Family History

The inverse relation found between solar insolation and the family history of mood disorders suggests that family members may also be affected by solar insolation levels.

Although diverse factors may contribute to the development of bipolar disorder, multiple studies have documented the association with family history, and noted involvement of potential genetic variants [24, 25]. Children of parents who have a serious mental illness, including bipolar disorder, have an increased risk of developing a psychiatric disorder, often in childhood [26–29]. Genes involved in the regulation of circadian rhythms and sleep have been linked to mental illness

TABLE 3 | Ratio of mean monthly minimum/mean monthly maximum insolation: Example onset locations by latitude group ($N=5842$).

Degrees latitude North + South	Onset location	Ratio of mean monthly minimum/mean monthly maximum insolation
0–9	Kampala, Uganda	0.8280
	Kuala Lumpur, Malaysia	0.8131
	Mataram, Indonesia	0.7830
	Medellín, Columbia	0.8046
	Singapore	0.8102
10–19	Bahir Dar, Ethiopia	0.7377
	Bangkok, Thailand	0.7842
	Bengaluru, India	0.7163
	Hyderabad, India	0.6793
	Mexico City, Mexico	0.7344
20–29	Salvador, Brazil	0.6355
	Hong Kong, China	0.5804
	São Paulo, Brazil	0.6079
	Taichung, Taiwan	0.4533
	Wardha, India	0.5839
30–39	Ankara, Turkey	0.2297
	Athens, Greece	0.2481
	Beer Sheva, Israel	0.3659
	Buenos Aires, Argentina	0.3105
	Cagliari, Italy	0.2510
	Cape Town, South Africa	0.3147
	Los Angeles, CA, USA	0.3585
	Melbourne, Australia	0.2600
	San Francisco, CA, USA	0.2976
	Santiago, Chile	0.2446
Seoul, South Korea	0.3969	
Tokyo, Japan	0.4899	
Tunis, Tunisia	0.3042	

(Continues)

TABLE 3 | (Continued)

Degrees latitude North + South	Onset location	Ratio of mean monthly minimum/mean monthly maximum insolation
40–49	Barcelona, Spain	0.2596
	Belgrade, Serbia	0.1794
	Boston, MA, USA	0.2381
	Christchurch, New Zealand	0.2303
	Grand Rapids, MI, USA	0.1866
	Halifax, Canada	0.2167
	Minneapolis, MN, USA	0.2018
	Paris, France	0.1417
	Rome, Italy	0.2211
	Siena, Italy	0.1934
50–59	Vienna, Austria	0.1374
	Würzburg, Germany	0.1240
	Aarhus, Denmark	0.0544
	Calgary, Canada	0.1368
	Dresden, Germany	0.1134
	Dublin, Ireland	0.1122
	Oslo, Norway	0.0369
	Poznan, Poland	0.0954
60+	Stockholm, Sweden	0.0321
	Tartu, Estonia	0.0411
	Helsinki, Finland	0.0299
	Trondheim, Norway	0.0170
	Khanti-Mansiysk, Russia	0.0357

[30]. An early onset of BD I in childhood is associated with a family history of mood disorders and poor functional outcomes [31, 32]. Genetic variants may also contribute to disruptions in sleep and circadian rhythms found in patients with bipolar disorders [12]. Polymorphisms in some clock genes may be linked to the course of BD I disorder [33]. Patients with bipolar disorder who have a family history of suicide in first-generation relatives are at a very high risk for suicide [25, 34]. Substance abuse and adverse childhood experiences are also risk factors for the onset of bipolar disorder [35]. Early intervention and support are often indicated for the child of a parent with bipolar disorder [29].

5.2 | Gender Differences

Although the prevalence of bipolar disorder is similar between males and females, the presentation of symptoms and disease course may differ between the genders [36–38]. Females may have an increased risk of hypomania, rapid cycling mixed episodes, and experience mood changes across the menstrual cycle [39, 40]. Males may have an earlier age of onset of mania and bipolar disorder [41]. Females may spend a larger proportion of time with depressive symptoms [42–44]. The risk of suicide attempts is higher in females than males [45–47], but completed suicide is more common in males [48]. About 65% of individuals with bipolar disorder have one or more concurrent psychiatric disorders [49]. Males have an increased risk of simultaneous substance use and alcohol misuse disorders [49]. Females have an increased risk of anxiety and eating disorders, and of medical comorbidities including autoimmune and inflammatory disorders [44, 49, 50]. Both genders have an increased risk of cardiovascular disease which contributes to premature mortality [49, 51]. There may be gender differences in some laboratory test results in patients with bipolar disorder [52, 53]. There may be gender differences in response to treatments for bipolar disorder [37]. Women may be more concerned about side effects such as weight gain which may decrease medication adherence [54, 55]. Additionally, treatment of females for bipolar disorder must consider reproductive issues, including menstruation, childbirth and postpartum periods [36, 39, 54].

6 | Limitations

Data collection methods were not standardized across the data collection sites. This analysis assumes that if the birth location is the same as the onset location of the patients in the database with BD I, the patient onset location is the same as the family location. A primary limitation was that family history was derived from the patient data, rather than by interviewing family members, and misclassification might bias the findings. Socioeconomic factors were not available that might influence reporting of family history. Individual variability and gender differences in light sensitivity, and the impacts of light pollution were not analyzed [56–60]. Light exposure patterns may differ between genders, as in the US, with females receiving less bright light than males [61]. Time of day differences in response to light exposure were not included [62]. Daily and seasonal differences in the spectral composition of light were not analyzed [63]. Seasonal patterns of patient mood variation were not available [64, 65]. The effects of living in urban, industrialized areas on light exposure were omitted [66]. The impacts of artificial light, including from occupational exposure and urbanization, may include suppression of melatonin release, interference with circadian rhythms, and adverse health effects [67, 68]. No genetic data were available. The negative effects of excessive sun exposure such as the risk of skin cancer were omitted [69]. This study did not discuss bipolar II disorder which may be more frequent in females [43, 70].

7 | Conclusion

This study suggests that sunlight may affect the patient's family as well as the patients who have BD I with increased risk closer

to the poles. Given the profound effects of sunlight on human life, health, and physiology, it is important to recognize the associations between family history, solar insolation, and gender. Psychiatrists should realize that the family of patients with mood disorders who live in the same location and experience the same solar insolation, especially females, may be at increased risk for a mood disorder.

Author Contributions

M.B. and T.G. completed the initial draft of the manuscript, which was reviewed and approved by all authors.

Acknowledgments

Open Access funding enabled and organized by Projekt DEAL.

Funding

This research was supported by funds from the Medical Faculty, Dresden University of Technology, Dresden, Germany, to Michael Bauer.

Affiliations

¹Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Faculty of Medicine, Technical University Dresden, Dresden, Germany | ²ChronoRecord Association, Fullerton, California, USA | ³Department of Psychiatry, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA | ⁴Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada | ⁵Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey | ⁶Department of Psychiatry, Atlas University, Istanbul, Turkey | ⁷Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway | ⁸Department of Psychiatry, National and Capodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece | ⁹Section of Neurosciences and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Sardinia, Italy | ¹⁰Department of Psychiatry, Selcuk University Faculty of Medicine, Konya, Turkey | ¹¹Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, Cologne, Germany | ¹²Department of Psychiatry, University of Münster, Münster, Germany | ¹³Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia | ¹⁴The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia | ¹⁵University Hospital, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany | ¹⁶National Institute of Psychiatry “Ramón de la Fuente Muñiz”, Mexico City, Mexico | ¹⁷Department of Pediatrics and Human Development, Michigan State University, Grand Rapids, Michigan, USA | ¹⁸Department of Psychiatry, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia | ¹⁹Bipolar Disorder Research Program, Department of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil | ²⁰Département de Psychiatrie et de Médecine Addictologique, Assistance Publique – Hôpitaux de Paris, INSERM UMR-S1144, Université Paris-Cité, FondaMental Foundation, Paris, France | ²¹Professor Emeritus of Psychiatry, Ben Gurion University of the Negev, Beer Sheva, Israel | ²²University Vita-Salute San Raffaele, Milan, Italy | ²³Ircs Ospedale San Raffaele, Milano, Italy | ²⁴IMPACT – The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia | ²⁵Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia | ²⁶Department of Psychiatry, Faculty of Health Sciences, Beer Sheva Mental Health Center, Ben Gurion University of the Negev, Beer Sheva,

Israel | ²⁷Department of Psychiatry, Baskent University Faculty of Medicine, Ankara, Turkey | ²⁸Butabika Hospital, Kampala, Uganda | ²⁹Department of Psychiatry, Trinity College Dublin, St Patrick’s University Hospital, Dublin, Ireland | ³⁰Mood Disorders Clinic, Dr. Jose Horwitz Psychiatric Institute, Santiago de Chile, Chile | ³¹Department of Mental Health and Substance Abuse, Piacenza, Italy | ³²Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan | ³³Private Practice, Central, Hong Kong, China | ³⁴Department of Psychiatry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece | ³⁵Department of Psychological Medicine, University of Otago, Christchurch, New Zealand | ³⁶Department of Molecular Medicine, University of Siena School of Medicine, Siena, Italy | ³⁷Pine Rest Christian Mental Health Services, Grand Rapids, Michigan, USA | ³⁸Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia | ³⁹Division of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria | ⁴⁰Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland | ⁴¹The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada | ⁴²Department of Psychiatry & Psychology, Mayo Clinic Depression Center, Mayo Clinic, Rochester, Minnesota, USA | ⁴³Département de psychiatrie et d’addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France | ⁴⁴Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France | ⁴⁵NeuroDiderot, Inserm, Université de Paris, Paris, France | ⁴⁶Department of Psychiatry, GHU Paris Psychiatrie & Neurosciences, Université de Paris, Paris, France | ⁴⁷Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, California, USA | ⁴⁸BIOARABA. Department of Psychiatry, University Hospital of Alava, University of the Basque Country, CIBERSAM, Vitoria, Spain | ⁴⁹Department of Psychiatry, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA | ⁵⁰Mood Disorders Center of Ottawa and the Department of Psychiatry, University of Toronto, Canada | ⁵¹Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands | ⁵²Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya, Tokyo, Japan | ⁵³Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil | ⁵⁴Programa de Pós-Graduação em Psicologia, Departamento de Psicologia do Desenvolvimento e da Personalidade, Instituto de Psicologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil | ⁵⁵Department of Clinical Research, University of Southern Denmark, Odense, Denmark | ⁵⁶INSERM, IMRB, Translational Neuropsychiatry, APHP, Mondor Univ Hospitals, Fondation FondaMental, Université Paris Est Créteil, Créteil, France | ⁵⁷Université Paris Saclay, CEA, Neurospin, Gif-sur-Yvette, France | ⁵⁸Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland | ⁵⁹National Institute for Health and Welfare, Helsinki, Finland | ⁶⁰University Clinical Center of Serbia, Clinic for Psychiatry, Belgrade, Serbia | ⁶¹Department of Psychiatry, University of Tartu, Tartu, Estonia | ⁶²Unit for Psychiatric Research, Aalborg University Hospital, Aalborg, Denmark | ⁶³Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden | ⁶⁴Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark | ⁶⁵Department of Psychiatry, Chosun University School of Medicine, Gwangju, Republic of Korea | ⁶⁶BIPOLAR Zentrum Wiener Neustadt, Wiener Neustadt, Austria | ⁶⁷Khanty-Mansiysk Clinical Psychoneurological Hospital, Khanty-Mansiysk, Russia | ⁶⁸Department of Neuroscience, Michigan State University, East Lansing, Michigan, USA | ⁶⁹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden | ⁷⁰Mental Health Department Odense, University Clinic and Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark | ⁷¹Psychiatry – Aalborg University Hospital, Aalborg, Denmark | ⁷²Department of Clinical Medicine, Aalborg University, Aalborg, Denmark | ⁷³Mood Disorders Program, Hospital Universitario San Vicente Fundación, Research

Group in Psychiatry, Department of Psychiatry, Faculty of Medicine, Universidad de Antioquia, Medellín, Colombia | ⁷⁴Forensic Psychiatry, University of Glasgow, NHS Greater Glasgow and Clyde, Glasgow, UK | ⁷⁵Copenhagen University Hospitals, Psychiatric Centre Copenhagen, Copenhagen, Denmark | ⁷⁶Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, India | ⁷⁷Department of Psychiatry, Faculty of Medicine, Mataram University, Mataram, Indonesia | ⁷⁸Razi Hospital, Faculty of Medicine, University of Tunis-ElManar, Tunis, Tunisia | ⁷⁹Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada | ⁸⁰Section of Psychiatry, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy | ⁸¹Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy | ⁸²Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts, USA | ⁸³School of Pharmacy, University of the Basque Country (UPV/EHU). Basque Sustainable Pharmacy and Biotherapy Research Group, 01006 Vitoria-Gasteiz, Spain | ⁸⁴Osakidetza-Basque Health Service, BioAraba Health Research Institute, 01006 Vitoria-Gasteiz, Spain | ⁸⁵Faculty of Health Sciences, International University of La Rioja (UNIR), Neurohealth Research Group, 26006 Logroño, Spain | ⁸⁶Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan | ⁸⁷Dept of Psychiatry & Trinity College Institute of Neuroscience, Trinity College Dublin, St Patrick's University Hospital, Dublin, Ireland | ⁸⁸Department of Child and Adolescent Psychiatry and Psychotherapy, SHG Klinikum, Idar-Oberstein, Germany | ⁸⁹Department of Mood and Anxiety Disorders, Institute of Mental Health, Singapore, Singapore | ⁹⁰Michigan State University College of Human Medicine, Traverse City Campus, Traverse City, Michigan, USA | ⁹¹Department of Mental Health, St Olav University Hospital, Trondheim, Norway | ⁹²Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology – NTNU, Trondheim, Norway | ⁹³Soviet Psychoneurological Hospital, Ural, Russia | ⁹⁴Department of Psychiatry, University of California San Diego, San Diego, California, USA | ⁹⁵Makunda Christian Leprosy and General Hospital, Bazaricherra, Assam, India | ⁹⁶Department of Psychiatry, NorthWest Area Mental Health Service, Northern Hospital, Melbourne, Australia | ⁹⁷Affective Disorders Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, Japan | ⁹⁸Tunisian Bipolar Forum, Tunis, Tunisia | ⁹⁹Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand | ¹⁰⁰Hospital “Ángeles del Pedregal”, Mexico City, Mexico | ¹⁰¹Lucio Bini Mood Disorder Center, Cagliari, Italy | ¹⁰²Department of Neurosciences, Mental Health and Sensory Organs, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy | ¹⁰³School of Medicine, Universidad Diego Portales CL, Santiago de Chile, Chile | ¹⁰⁴School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK | ¹⁰⁵SAMRC Genomic and Precision Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa | ¹⁰⁶Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Palo Alto, California, USA | ¹⁰⁷Asha Bipolar Clinic, Asha Hospital, Hyderabad, Telangana, India | ¹⁰⁸Department of Psychiatry, Epidemiology, and Internal Medicine, Iowa Neuroscience Institute, The University of Iowa, Iowa City, Iowa, USA | ¹⁰⁹Department of Neuroscience and Mental Health, Federal University of Bahia, Salvador, Brazil | ¹¹⁰Bipolar Zentrum Wiener Neustadt, Sigmund Freud Privat Universität, Vienna, Austria | ¹¹¹Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK | ¹¹²AREA, Assistance and Research in Affective Disorders, Buenos Aires, Argentina | ¹¹³Science Directorate/Climate Science Branch, National Aeronautics and Space Administration (NASA) Langley Research Center, Hampton, Virginia, USA | ¹¹⁴SAMRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry & Neuroscience Institute, University of Cape Town, Cape Town, South Africa | ¹¹⁵College of Medicine, China Medical University (CMU), Taichung, Taiwan | ¹¹⁶An-Nan Hospital, China Medical University, Tainan, Taiwan | ¹¹⁷Research Division, Institute of Mental Health, Singapore | ¹¹⁸Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia | ¹¹⁹Mutual Insurance Company Ilmarinen, Helsinki,

Finland | ¹²⁰Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia | ¹²¹McLean Hospital-Harvard Medical School, Boston, Massachusetts, USA | ¹²²Mood Disorder Lucio Bini Centers, Cagliari, Italy | ¹²³Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain | ¹²⁴Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Institute of Neurosciences (UBNeuro), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain | ¹²⁵Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, Australia | ¹²⁶Subdirección de Investigaciones Clínicas. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico | ¹²⁷Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

Conflicts of Interest

Lars Vedel Lessing has within the recent 3 years been a consultant for Lundbeck and Teva. Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, AbbVie, Adamed, Adium, Alcediag, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Casen-Recordati, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Esteve, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Intra-Cellular therapies, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, MedinCell, Merck, Mitsubishi Tanabe Pharma, Newron, Novartis, Organon, Orion Corporation, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatrix outside the submitted work. All other authors have nothing to declare.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

1. C. Blume, C. Garbaza, and M. Spitschan, “Effects of Light on Human Circadian Rhythms, Sleep and Mood,” *Somnologie* 23, no. 3 (2019): 147–156.
2. A. Wirz-Justice, D. J. Skene, and M. Münch, “The Relevance of Daylight for Humans,” *Biochemical Pharmacology* 191 (2021): 114304.
3. R. G. Foster, “Sleep, Circadian Rhythms and Health,” *Interface Focus* 10, no. 3 (2020): 20190098.
4. National Aeronautics and Space Administration. NASA, “The Power Project,” (2024), <https://power.larc.nasa.gov/>.
5. M. Bauer, T. Glenn, M. Alda, et al., “Solar Insolation in Springtime Influences Age of Onset of Bipolar I Disorder,” *Acta Psychiatrica Scandinavica* 136, no. 6 (2017): 571–582.
6. M. Bauer, T. Glenn, M. Alda, et al., “Relationship Between Sunlight and the Age of Onset of Bipolar Disorder: An International Multisite Study,” *Journal of Affective Disorders* 167 (2014): 104–111.
7. T. Roenneberg, C. J. Kumar, and M. Merrow, “The Human Circadian Clock Entrain to Sun Time,” *Current Biology* 17, no. 2 (2007): R44–R45.
8. R. G. Foster, “Fundamentals of Circadian Entrainment by Light,” *Lighting Research & Technology* 53, no. 5 (2021): 377–393.
9. R. Allada and J. Bass, “Circadian Mechanisms in Medicine,” *New England Journal of Medicine* 384, no. 6 (2021): 550–561.
10. A. M. Rosenwasser and F. W. Turek, “Neurobiology of Circadian Rhythm Regulation,” *Sleep Medicine Clinics* 10, no. 4 (2015): 403–412.
11. M. Hatori and S. Panda, “The Emerging Roles of Melanopsin in Behavioral Adaptation to Light,” *Trends in Molecular Medicine* 16, no. 10 (2010): 435–446.

12. F. Bellivier, P. A. Geoffroy, B. Etain, and J. Scott, "Sleep-And Circadian Rhythm-Associated Pathways as Therapeutic Targets in Bipolar Disorder," *Expert Opinion on Therapeutic Targets* 19, no. 6 (2015): 747–763.
13. T. Roenneberg and M. Mewes, "The Circadian Clock and Human Health," *Current Biology* 26, no. 10 (2016): R432–R443.
14. W. H. Walker, J. C. Walton, A. C. DeVries, and R. J. Nelson, "Circadian Rhythm Disruption and Mental Health," *Translational Psychiatry* 10, no. 1 (2020): 28.
15. M. F. Holick, "Biological Effects of Sunlight, Ultraviolet Radiation, Visible Light, Infrared Radiation and Vitamin D for Health," *Anticancer Research* 36, no. 3 (2016): 1345–1356.
16. S. L. Zeger and K. Y. Liang, "Longitudinal Data Analysis for Discrete and Continuous Outcomes," *Biometrics* 42 (1986): 121–130.
17. US Department of Energy, "Solar Energy Basics," (2025), <https://www.energy.gov/eere/solar/solar-radiation-basics>.
18. A. S. Erem and M. S. Razzaque, "Vitamin D-Independent Benefits of Safe Sunlight Exposure," *Journal of Steroid Biochemistry and Molecular Biology* 213 (2021): 105957.
19. R. B. Weller, "Sunlight Has Cardiovascular Benefits Independently of Vitamin D," *Blood Purification* 41, no. 1–3 (2016): 130–134.
20. S. Paul and T. M. Brown, "Direct Effects of the Light Environment on Daily Neuroendocrine Control," *Journal of Endocrinology* 243, no. 1 (2019): R1–R8.
21. M. Münch, A. E. Brøndsted, S. A. Brown, et al., "The Effect of Light on Humans," in *Changing Perspectives on Daylight: Science, Technology, and Culture* (Science/AAAS. Sponsored supplement to Science/AAAS, 2017), 16–23.
22. D. G. Hoel, M. Berwick, F. R. de Grujil, and M. F. Holick, "The Risks and Benefits of Sun Exposure," *Dermato-Endocrinology* 8, no. 1 (2016): e1248325.
23. J. Maruani and P. A. Geoffroy, "Multi-Level Processes and Retina-Brain Pathways of Photic Regulation of Mood," *Journal of Clinical Medicine* 11, no. 2 (2022): 448.
24. N. Craddock, M. C. O'Donovan, and M. J. Owen, "The Genetics of Schizophrenia and Bipolar Disorder: Dissecting Psychosis," *Journal of Medical Genetics* 42, no. 3 (2005): 193–204.
25. G. Kalcev, A. Preti, A. Scano, G. Orrù, and M. G. Carta, "Insight Into Susceptibility Genes Associated With Bipolar Disorder: A Systematic Review," *European Review for Medical and Pharmacological Sciences* 25, no. 18 (2021): 5701–5724.
26. A. A. Thorup, T. M. Laursen, T. Munk-Olsen, et al., "Incidence of Child and Adolescent Mental Disorders in Children Aged 0-17 With Familial High Risk for Severe Mental Illness-A Danish Register Study," *Schizophrenia Research* 197 (2018): 298–304.
27. D. Rasic, T. Hajek, M. Alda, and R. Uher, "Risk of Mental Illness in Offspring of Parents With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Meta-Analysis of Family High-Risk Studies," *Schizophrenia Bulletin* 40, no. 1 (2014): 28–38.
28. R. Uher, B. Pavlova, J. Radua, et al., "Transdiagnostic Risk of Mental Disorders in Offspring of Affected Parents: A Meta-Analysis of Family High-Risk and Registry Studies," *World Psychiatry* 22, no. 3 (2023): 433–448.
29. C. Takami Lageborn, M. Zhou, M. Boman, et al., "Childhood and Adolescence Outcomes in Offspring to Parents With Bipolar Disorder: The Impact of Lifetime Parental Comorbidity, Parental Sex, and Bipolar Subtype," *Journal of Child Psychology and Psychiatry* 65, no. 10 (2024): 1355–1368.
30. A. Jagannath, S. N. Peirson, and R. G. Foster, "Sleep and Circadian Rhythm Disruption in Neuropsychiatric Illness," *Current Opinion in Neurobiology* 23, no. 5 (2013): 888–894.
31. R. J. Baldessarini, L. Tondo, G. H. Vázquez, et al., "Age at Onset Versus Family History and Clinical Outcomes in 1,665 International Bipolar-I Disorder Patients," *World Psychiatry* 11, no. 1 (2012): 40–46.
32. R. M. Post, G. S. Leverich, R. Kupka, et al., "Increased Parental History of Bipolar Disorder in the U Nited States: Association With Early Age of Onset," *Acta Psychiatrica Scandinavica* 129, no. 5 (2014): 375–382.
33. K. Wulff, S. Gatti, J. G. Wettstein, and R. G. Foster, "Sleep and Circadian Rhythm Disruption in Psychiatric and Neurodegenerative Disease," *Nature Reviews Neuroscience* 11, no. 8 (2010): 589–599.
34. S. Romero, F. Colom, A. M. Iosif, et al., "Relevance of Family History of Suicide in the Long-Term Outcome of Bipolar Disorders," *Journal of Clinical Psychiatry* 68, no. 10 (2007): 1517–1521.
35. N. Robinson, A. Ploner, M. Leone, P. Lichtenstein, K. S. Kendler, and S. E. Bergen, "Environmental Risk Factors for Schizophrenia and Bipolar Disorder From Childhood to Diagnosis: A Swedish Nested Case-Control Study," *Psychological Medicine* 54, no. 9 (2024): 2162–2171.
36. V. K. Burt and N. Rasgon, "Special Considerations in Treating Bipolar Disorder in Women," *Bipolar Disorders* 6 (2004): 2–13.
37. G. Menculini, J. L. Steardo, T. Sciarra, et al., "Sex Differences in Bipolar Disorders: Impact on Psychopathological Features and Treatment Response," *Frontiers in Psychiatry* 13 (2022): 926594.
38. R. Palacios-Garran, S. Amoretti, M. Serra-Navarro, et al., "Sex Matters: Differences in Prodromes, Clinical and Neuropsychological Features in Individuals With a First Episode Mania or Psychosis," *Journal of Affective Disorders* 369 (2025): 449–461.
39. A. Diflorio and I. Jones, "Is Sex Important? Gender Differences in Bipolar Disorder," *International Review of Psychiatry* 22 (2010): 437–452.
40. N. Rasgon, M. Bauer, P. Grof, et al., "Sex-Specific Self-Reported Mood Changes by Patients With Bipolar Disorder," *Journal of Psychiatric Research* 39, no. 1 (2005): 77–83.
41. N. Kennedy, J. Boydell, S. Kalidindi, et al., "Gender Differences in Incidence and Age at Onset of Mania and Bipolar Disorder Over a 35-Year Period in Camberwell, England," *American Journal of Psychiatry* 162, no. 2 (2005): 257–262.
42. L. L. Altshuler, R. W. Kupka, G. Helleman, et al., "Gender and Depressive Symptoms in 711 Patients With Bipolar Disorder Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Outcome Network," *American Journal of Psychiatry* 167, no. 6 (2010): 708–715.
43. B. Dell'Osso, L. Cremaschi, M. Macellaro, and R. Cafaro, "Gender and Sex Issues in Bipolar Disorder," *Psychiatric Times* 39, no. 6 (2022): 36–38.
44. A. Miola, L. Tondo, and R. J. Baldessarini, "Gender Differences in 4466 Mood Disorder Patients," *European Journal of Psychiatry* 39, no. 3 (2025): 100303.
45. L. Tondo, M. Pompili, A. Forte, and R. J. Baldessarini, "Suicide Attempts in Bipolar Disorders: Comprehensive Review of 101 Reports," *Acta Psychiatrica Scandinavica* 133, no. 3 (2016): 174–186.
46. F. H. Hu, Y. J. Jia, D. Y. Zhao, et al., "Gender Differences in Suicide Among Patients With Bipolar Disorder: A Systematic Review and Meta-Analysis," *Journal of Affective Disorders* 339 (2023): 601–614.
47. P. Ritter, T. Glenn, E. D. Achtyes, et al., "Association Between a Large Change Between the Minimum and Maximum Monthly Values of Solar Insolation and a History of Suicide Attempts in Bipolar I Disorder," *International Journal of Bipolar Disorders* 12, no. 1 (2024): 43.
48. L. Plans, C. Barrot, E. Nieto, et al., "Association Between Completed Suicide and Bipolar Disorder: A Systematic Review of the Literature," *Journal of Affective Disorders* 242 (2019): 111–122.
49. A. A. Nierenberg, B. Agustini, O. Köhler-Forsberg, et al., "Diagnosis and Treatment of Bipolar Disorder: A Review," *JAMA* 330, no. 14 (2023): 1370–1380.

50. R. S. Patel, S. Virani, H. Saeed, S. Nimmagadda, J. Talukdar, and N. A. Youssef, "Gender Differences and Comorbidities in US Adults With Bipolar Disorder," *Brain Sciences* 8, no. 9 (2018): 168.
51. J. K. N. Chan, C. Z. Fang, H. K. Y. Lo, C. S. M. Wong, N. C. L. Yung, and W. C. Chang, "Pre-Existing Chronic Physical Morbidity and Excess Mortality in People With Bipolar Disorder: A Population-Based Cohort Study in 2008-2018," *European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology* 84 (2024): 20.
52. L. Piccirilli, E. Capuzzi, F. Legnani, et al., "Gender Differences in Clinical and Biochemical Variables of Patients Affected by Bipolar Disorder," *Brain Sciences* 15, no. 2 (2025): 214.
53. L. Fusar-Poli, A. Amerio, P. Cimpoesu, et al., "Gender Differences in Complete Blood Count and Inflammatory Ratios Among Patients With Bipolar Disorder," *Brain Sciences* 11, no. 3 (2021): 363.
54. P. Vega, S. Barbeito, S. R. De Azúa, et al., "Bipolar Disorder Differences Between Genders: Special Considerations for Women," *Women's Health* 7, no. 6 (2011): 663-676.
55. K. Kriegshauser, M. Sajatovic, J. H. Jenkins, et al., "Gender Differences in Subjective Experience and Treatment of Bipolar Disorder," *Journal of Nervous and Mental Disease* 198, no. 5 (2010): 370-372.
56. S. L. Chellappa, R. Steiner, P. Oelhafen, and C. Cajochen, "Sex Differences in Light Sensitivity Impact on Brightness Perception, Vigilant Attention and Sleep in Humans," *Scientific Reports* 7, no. 1 (2017): 14215.
57. E. M. McGlashan, G. R. Poudel, P. Vidafar, S. P. Drummond, and S. W. Cain, "Imaging Individual Differences in the Response of the Human Suprachiasmatic Area to Light," *Frontiers in Neurology* 9 (2018): 1022.
58. M. Spitschan and N. Santhi, "Individual Differences and Diversity in Human Physiological Responses to Light," *eBioMedicine* 75 (2022): 103640.
59. A. J. Phillips, P. Vidafarn, A. C. Burns, et al., "High Sensitivity and Interindividual Variability in the Response of the Human Circadian System to Evening Light," *National Academy of Sciences of the United States of America* 116, no. 24 (2019): 12019-12024.
60. L. Tähkämö, T. Partonen, and A. K. Pesonen, "Systematic Review of Light Exposure Impact on Human Circadian Rhythm," *Chronobiology International* 36, no. 2 (2019): 151-170.
61. D. A. Wallace, "Light Exposure Differs by Sex in the US, With Females Receiving Less Bright Light," *Npj Biological Timing and Sleep* 1, no. 1 (2024): 1.
62. M. Ruger, M. C. Gordijn, D. G. Beersma, B. De Vries, and S. Daan, "Time-Of-Day-Dependent Effects of Bright Light Exposure on Human Psychophysiology: Comparison of Daytime and Nighttime Exposure," *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology* 290, no. 5 (2006): R1413-R1420.
63. H. C. Thorne, K. H. Jones, S. P. Peters, S. N. Archer, and D. J. Dijk, "Daily and Seasonal Variation in the Spectral Composition of Light Exposure in Humans," *Chronobiology International* 26, no. 5 (2009): 854-866.
64. P. A. Geoffroy, F. Bellivier, J. Scott, et al., "Bipolar Disorder With Seasonal Pattern: Clinical Characteristics and Gender Influences," *Chronobiology International* 30, no. 9 (2013): 1101-1107.
65. P. A. Geoffroy, F. Bellivier, J. Scott, and B. Etain, "Seasonality and Bipolar Disorder: A Systematic Review, From Admission Rates to Seasonality of Symptoms," *Journal of Affective Disorders* 168 (2014): 10-23.
66. M. Münch, A. Wirz-Justice, S. A. Brown, et al., "The Role of Daylight for Humans: Gaps in Current Knowledge," *Clocks & Sleep* 2, no. 1 (2020): 61-85.
67. D. Blask, G. Brainard, R. Gibbons, S. Lockey, and M. Motta, "Light Pollution: Adverse Health Effects of Nighttime Lighting," *Report 4 of the Council on Science and Public Health (A-12)* 4 (2012): 4-5.
68. R. M. Lunn, D. E. Blask, A. N. Coogan, et al., "Health Consequences of Electric Lighting Practices in the Modern World: A Report on the National Toxicology Program's Workshop on Shift Work at Night, Artificial Light at Night, and Circadian Disruption," *Science of the Total Environment* 607 (2017): 1073-1084.
69. H. van der Rhee, E. de Vries, C. Coomans, P. van de Velde, and J. W. Coebergh, "Sunlight: For Better or for Worse? A Review of Positive and Negative Effects of Sun Exposure," *Cancer Research Frontiers* 2, no. 2 (2016): 156-183.
70. A. Karanti, M. Kardell, E. Joas, B. Runeson, E. Pålsson, and M. Landén, "Characteristics of Bipolar I and II Disorder: A Study of 8766 Individuals," *Bipolar Disorders* 22, no. 4 (2020): 392-400.